KaraLeanneBickhamMD

Clinical Director, Vaccine Late Stage Development Merck Research Laboratories

Dr. Bickham is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
34 Route 403
Garrison, NY 10524
Phone+1 845-424-4444

Fax+1 845-424-4664

New York Presbyterian Hospital (Cornell Campus)Residency, Pediatrics, 1994 - 1997
University of Texas Southwestern Medical SchoolClass of 1994

PubMed

Corrigendum to "A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114...
Federico Martinon-Torres, Jacek Wysocki, Leszek Szenborn, Alfonso Carmona-Martinez, Airi Poder
Vaccine. 2025-02-27
1 citations
Safety and Immunogenicity of V114 in Preterm Infants: A Pooled Analysis of Four Phase Three Studies.
Timothy J Chapman, Shrita M Patel, Sheryl A Flores, Shengjie Xu, Robert Lupinacci
The Pediatric Infectious Disease Journal. 2023-11-01
6 citations
Safety and Tolerability of V114 Pneumococcal Vaccine in Infants: A Phase 3 Study.
Natalie Banniettis, Michael Horn, Manish Sadarangani, Shrita M Patel, David Greenberg
Pediatrics. 2023-07-01

Merck's Vaxneuvance Lead Departs to Help Develop Rival Vaccine at AffinivaxAugust 9th, 2021